The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer

Elena Theophanous, Constantina Petraki, Andreas Scorilas, Vassilios Komborozos, George Veloudis, Jozsef L. Varga, Marta Zarandi, Andrew V Schally, Michael Koutsilieris

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the release of GH from the pituitary gland. The receptors for GHRH (GHRH-R) are expressed predominantly in the pituitary. Recent evidence demonstrates that splice variants of the GHRH receptor are also expressed in several nonpituitary tissues, both normal and tumoral, as well as in cancer cell lines. The aim of this study was to investigate the expression of the splice variant 1 (SV-1) of GHRH-R in colorectal cancer (CRC). Seventy patients who underwent partial colectomy for CRC were enrolled in the study. Immunohistochemical expression of SV-1 was studied in paraffin-embedded sections of patient tumor tissue. A cytoplasmic supranuclear expression of SV-1 was observed in CRC as well as in the normal colon mucosa. Tumor grade and pathological stage were negatively correlated with expression of SV-1 ( P = 0.012 and P = 0.013, respectively). CRCs metastatic to the liver showed a lower expression of SV-1 than did primary tumors, but this difference was not statistically significant. Kaplan-Meier and Cox univariate survival analyses indicated an improved survival time in patients with high SV-1 compared with those with low GHRH-R expression, but this difference was not statistically significant. The immunohistochemical expression of SV-1 seems to be a favorable prognostic factor in CRC.

Original languageEnglish
Pages (from-to)242-247
Number of pages6
JournalMolecular Medicine
Volume15
Issue number7-8
DOIs
StatePublished - Jul 1 2009

Fingerprint

Colorectal Neoplasms
Hormones
Neoplasms
Hypothalamic Hormones
Growth Hormone-Releasing Hormone
Colectomy
Pituitary Gland
Survival Analysis
Paraffin
Growth Hormone
Colon
Mucous Membrane
somatotropin releasing hormone receptor
Cell Line
Survival
Liver

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. / Theophanous, Elena; Petraki, Constantina; Scorilas, Andreas; Komborozos, Vassilios; Veloudis, George; Varga, Jozsef L.; Zarandi, Marta; Schally, Andrew V; Koutsilieris, Michael.

In: Molecular Medicine, Vol. 15, No. 7-8, 01.07.2009, p. 242-247.

Research output: Contribution to journalArticle

Theophanous, E, Petraki, C, Scorilas, A, Komborozos, V, Veloudis, G, Varga, JL, Zarandi, M, Schally, AV & Koutsilieris, M 2009, 'The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer', Molecular Medicine, vol. 15, no. 7-8, pp. 242-247. https://doi.org/10.2119/molmed.2008.00132
Theophanous, Elena ; Petraki, Constantina ; Scorilas, Andreas ; Komborozos, Vassilios ; Veloudis, George ; Varga, Jozsef L. ; Zarandi, Marta ; Schally, Andrew V ; Koutsilieris, Michael. / The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. In: Molecular Medicine. 2009 ; Vol. 15, No. 7-8. pp. 242-247.
@article{eb90b2f9345e41b29bf9937d0fcb8c71,
title = "The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer",
abstract = "Hypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the release of GH from the pituitary gland. The receptors for GHRH (GHRH-R) are expressed predominantly in the pituitary. Recent evidence demonstrates that splice variants of the GHRH receptor are also expressed in several nonpituitary tissues, both normal and tumoral, as well as in cancer cell lines. The aim of this study was to investigate the expression of the splice variant 1 (SV-1) of GHRH-R in colorectal cancer (CRC). Seventy patients who underwent partial colectomy for CRC were enrolled in the study. Immunohistochemical expression of SV-1 was studied in paraffin-embedded sections of patient tumor tissue. A cytoplasmic supranuclear expression of SV-1 was observed in CRC as well as in the normal colon mucosa. Tumor grade and pathological stage were negatively correlated with expression of SV-1 ( P = 0.012 and P = 0.013, respectively). CRCs metastatic to the liver showed a lower expression of SV-1 than did primary tumors, but this difference was not statistically significant. Kaplan-Meier and Cox univariate survival analyses indicated an improved survival time in patients with high SV-1 compared with those with low GHRH-R expression, but this difference was not statistically significant. The immunohistochemical expression of SV-1 seems to be a favorable prognostic factor in CRC.",
author = "Elena Theophanous and Constantina Petraki and Andreas Scorilas and Vassilios Komborozos and George Veloudis and Varga, {Jozsef L.} and Marta Zarandi and Schally, {Andrew V} and Michael Koutsilieris",
year = "2009",
month = "7",
day = "1",
doi = "10.2119/molmed.2008.00132",
language = "English",
volume = "15",
pages = "242--247",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "7-8",

}

TY - JOUR

T1 - The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer

AU - Theophanous, Elena

AU - Petraki, Constantina

AU - Scorilas, Andreas

AU - Komborozos, Vassilios

AU - Veloudis, George

AU - Varga, Jozsef L.

AU - Zarandi, Marta

AU - Schally, Andrew V

AU - Koutsilieris, Michael

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Hypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the release of GH from the pituitary gland. The receptors for GHRH (GHRH-R) are expressed predominantly in the pituitary. Recent evidence demonstrates that splice variants of the GHRH receptor are also expressed in several nonpituitary tissues, both normal and tumoral, as well as in cancer cell lines. The aim of this study was to investigate the expression of the splice variant 1 (SV-1) of GHRH-R in colorectal cancer (CRC). Seventy patients who underwent partial colectomy for CRC were enrolled in the study. Immunohistochemical expression of SV-1 was studied in paraffin-embedded sections of patient tumor tissue. A cytoplasmic supranuclear expression of SV-1 was observed in CRC as well as in the normal colon mucosa. Tumor grade and pathological stage were negatively correlated with expression of SV-1 ( P = 0.012 and P = 0.013, respectively). CRCs metastatic to the liver showed a lower expression of SV-1 than did primary tumors, but this difference was not statistically significant. Kaplan-Meier and Cox univariate survival analyses indicated an improved survival time in patients with high SV-1 compared with those with low GHRH-R expression, but this difference was not statistically significant. The immunohistochemical expression of SV-1 seems to be a favorable prognostic factor in CRC.

AB - Hypothalamic growth hormone (GH)-releasing hormone (GHRH) regulates the release of GH from the pituitary gland. The receptors for GHRH (GHRH-R) are expressed predominantly in the pituitary. Recent evidence demonstrates that splice variants of the GHRH receptor are also expressed in several nonpituitary tissues, both normal and tumoral, as well as in cancer cell lines. The aim of this study was to investigate the expression of the splice variant 1 (SV-1) of GHRH-R in colorectal cancer (CRC). Seventy patients who underwent partial colectomy for CRC were enrolled in the study. Immunohistochemical expression of SV-1 was studied in paraffin-embedded sections of patient tumor tissue. A cytoplasmic supranuclear expression of SV-1 was observed in CRC as well as in the normal colon mucosa. Tumor grade and pathological stage were negatively correlated with expression of SV-1 ( P = 0.012 and P = 0.013, respectively). CRCs metastatic to the liver showed a lower expression of SV-1 than did primary tumors, but this difference was not statistically significant. Kaplan-Meier and Cox univariate survival analyses indicated an improved survival time in patients with high SV-1 compared with those with low GHRH-R expression, but this difference was not statistically significant. The immunohistochemical expression of SV-1 seems to be a favorable prognostic factor in CRC.

UR - http://www.scopus.com/inward/record.url?scp=67650499256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650499256&partnerID=8YFLogxK

U2 - 10.2119/molmed.2008.00132

DO - 10.2119/molmed.2008.00132

M3 - Article

C2 - 19593408

AN - SCOPUS:67650499256

VL - 15

SP - 242

EP - 247

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 7-8

ER -